ValuEngine cut shares of VWR Corporation (NASDAQ:VWR) from a buy rating to a hold rating in a research report released on Wednesday morning.
Several other research firms also recently issued reports on VWR. Zacks Investment Research downgraded VWR Corporation from a buy rating to a hold rating in a research note on Thursday, October 5th. BidaskClub raised VWR Corporation from a strong sell rating to a sell rating in a research note on Saturday, September 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. VWR Corporation currently has an average rating of Hold and an average price target of $31.67.
VWR Corporation (NASDAQ VWR) traded up 0.045% during midday trading on Wednesday, reaching $33.095. 1,704,822 shares of the company’s stock traded hands. VWR Corporation has a 52-week low of $24.42 and a 52-week high of $37.25. The company has a market cap of $4.36 billion, a P/E ratio of 30.644 and a beta of 1.18. The stock has a 50-day moving average of $33.11 and a 200 day moving average of $32.08.
VWR Corporation (NASDAQ:VWR) last issued its earnings results on Monday, July 31st. The medical research company reported $0.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $0.04. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the firm earned $0.42 earnings per share. The business’s quarterly revenue was up 2.2% on a year-over-year basis. On average, analysts anticipate that VWR Corporation will post $1.86 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in VWR. BlackRock Inc. increased its position in VWR Corporation by 4,641.8% during the 1st quarter. BlackRock Inc. now owns 4,072,333 shares of the medical research company’s stock valued at $114,840,000 after purchasing an additional 3,986,452 shares during the period. Earnest Partners LLC increased its position in VWR Corporation by 116.8% during the 1st quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock valued at $50,678,000 after purchasing an additional 968,313 shares during the period. Macquarie Group Ltd. increased its position in VWR Corporation by 39.4% during the 1st quarter. Macquarie Group Ltd. now owns 1,933,570 shares of the medical research company’s stock valued at $54,527,000 after purchasing an additional 546,246 shares during the period. Vanguard Group Inc. increased its position in VWR Corporation by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 6,827,046 shares of the medical research company’s stock valued at $192,523,000 after purchasing an additional 345,117 shares during the period. Finally, Endurant Capital Management LP acquired a new stake in VWR Corporation during the 1st quarter valued at approximately $7,233,000.
About VWR Corporation
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.